Mr. Parfet has served as a director of the Company since 2005. Mr. Parfet has extensive knowledge and experience in executive management, accounting, finance, capital markets and international business. Mr. Parfet qualifies as a financial expert under SEC rules based on such experience, as detailed below, as well as his numerous leadership positions at national financial and accounting industry groups (including the EITF and FASB). He also has extensive ongoing Board experience through his current service as a director of two other public companies, as well as his prior service on the Board of other public companies. Mr. Parfet also has extensive Board committee experience.

Mr. Parfet is currently Chairman and Chief Executive Officer of MPI Research, a Michigan-based, privately-held pre-clinical toxicology research laboratory. He joined MPI Research in November 1995 as co-Chairman. From 1993 to 1996, he served as president and chief executive officer of Richard-Allan Medical Industries (now Thermo Fisher Scientific Inc.), a worldwide manufacturer of surgical and laboratory products. Prior to that, he had served in a variety of positions at The Upjohn Company, a pharmaceutical company, most recently as Vice Chairman of the Board. Mr. Parfet has served on the board of Monsanto Company since June 2000 (currently a member of the Audit, Executive and People and Compensation Committees) and Stryker Corporation since April 1993 (currently a member of the Audit, Governance and Nominating Committees, and is the Lead Independent Director). He also served as a director of PAREXEL International Corporation from June 2001 to May 2006 (served on the Executive, Audit and Compensation Committees), and a director of CMS Energy Corporation from November 1991 to May 2005 (served on the Audit, Executive, Finance and Pension, Organization and Compensation Committees).  Independent - Term Ends 2011

Above information per 2010 Proxy